Personalised Immunotherapy Platform

NCT06536257

Status	RECRUITING
Sponsor	Melanoma Institute Australia
Enrollment	1,000 participants

Plain Language Summary

This study creates a personalized immunotherapy testing platform that uses a patient's own tumor sample to predict whether immunotherapy will work for them before it is given. It covers both melanoma and other cancer types.

You may be eligible if...
- You have confirmed melanoma or another cancer type that is eligible for immunotherapy
- A tumor tissue sample is available that was collected before any systemic treatment
- Your cancer is measurable or detectable
- You have a life expectancy greater than 6 months

You may NOT be eligible if...
- You have active hepatitis B or C infection
- You have a known history of HIV or AIDS

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (25)

- MELANOMA:
- Written informed consent to participation for the use of tumour tissue, blood and stool and collection of standard clinical data.
- Histologically confirmed resected stage II (at high risk of recurrence of disease), III or stage IV melanoma (including cutaneous, mucosal, acral, subungual, uveal or unknown primary melanoma) and unresectable Stage III or IV melanoma
- Eligible to receive immunotherapy
- Availability of a melanoma tissue sample which was obtained at surgery and where no systemic treatments (e.g. adjuvant treatment) were administered between sample procurement and proposed PIP testing

... and 20 more (see full listing online)

Exclusion (3)

- \. Patients will be excluded if they have had a positive test result for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. If receiving treatment and from HCV for at least one year, patients are allowed to participate. No new testing is required for the sole purpose of this pilot phase. Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). No new testing is required
- NON-MELANOMA:
- \. Patients will be excluded if they have had a positive test result for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. If receiving treatment and from HCV for at least one year, patients are allowed to participate. No new testing is required for the sole purpose of this pilot phase. Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). No new testing is required

Locations (3 total)

Chris O'Brien Lifehouse, Sydney, New South Wales, Australia

Melanoma Institute Australia, Sydney, New South Wales, Australia
Westmead Hospital, Sydney, New South Wales, Australia